Form 4: RA Capital Reduces Vor Biopharma Stake

RA Capital Management, a 10% owner and director of Vor Biopharma Inc., sold a total of 221,166 shares of common stock over three days in late October 2025.

Summary

• RA Capital Management, L.P., along with its affiliated entities and managing members (Peter Kolchinsky and Rajeev Shah), reported sales of Vor Biopharma Inc. common stock.
• A total of 221,166 shares were sold across three separate transactions.
• The sales occurred on October 23, 2025 (76,880 shares), October 24, 2025 (53,345 shares), and October 27, 2025 (90,941 shares).
• Weighted average sale prices ranged from $28.01 to $28.12 per share.
• Following these transactions, RA Capital Healthcare Fund L.P. indirectly holds 1,180,060 shares of Vor Biopharma common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 3

Explanation: The sale of a significant number of shares by a 10% owner and director, RA Capital Management, L.P., is generally a bearish signal, even if executed under a pre-planned 10b5-1 program. It suggests a reduction in conviction or a belief that the stock is adequately valued.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not based on immediate, material non-public information, which can mitigate concerns about opportunistic trading.

Negatives

• RA Capital Management, a significant 10% owner and director, reduced its beneficial ownership in Vor Biopharma Inc. by 221,166 shares.
• The sales occurred at weighted average prices between $28.01 and $28.12 per share.
• The total beneficial ownership held indirectly by RA Capital Healthcare Fund L.P. decreased to 1,180,060 shares following these transactions.

Risks

• Insider selling by a major institutional investor and director could be interpreted by the market as a signal of reduced confidence in the company's near-term prospects or that the stock is fully valued.
• Increased selling pressure on the stock due to the volume of shares disposed of by a significant holder.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund'). The general partner of the Adviser is RA Capital Management GP, LLC (the 'Adviser GP'), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.
• Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• Ms. Sarah Reed, General Counsel of the Adviser, serves on the Issuer's board of directors.

Industry Context

This insider transaction report does not provide specific industry context, but insider selling by a major investor in the biopharma sector can sometimes be interpreted in the context of broader market sentiment towards the industry or specific therapeutic areas.

Related Party Transactions

• The transactions involve RA Capital Management, L.P., a 10% owner and director of Vor Biopharma Inc., and its affiliated entities and managing members, making them related party transactions by definition of insider trading rules.

Stakeholder Impact

• Shareholders may react negatively to the news of a major institutional investor and director reducing its stake, potentially leading to downward pressure on the stock price.
• The reduction in ownership by a significant investor could be interpreted as a decrease in long-term commitment to the company by a key stakeholder.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Vor Biopharma Inc. related to these transactions.

Key Dates

Recommendation

The sale of a substantial block of shares by a 10% owner and director, RA Capital Management, L.P., signals a reduction in insider confidence or a belief that the stock has reached an appropriate valuation. While executed under a 10b5-1 plan, the fundamental action of reducing exposure by a knowledgeable insider is a bearish indicator. Investors might consider reducing their own positions or exercising caution before initiating new ones.

Keywords

Vor Biopharma, VOR, RA Capital Management, Insider Selling, Form 4, Stock Sale, 10b5-1 Plan, Biopharma, Healthcare Investment